<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">2604</journal-id><journal-id journal-id-type="pmc-domain">ofid</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10368445</article-id><article-id pub-id-type="pmcid-ver">PMC10368445.1</article-id><article-id pub-id-type="pmcaid">10368445</article-id><article-id pub-id-type="pmcaiid">10368445</article-id><article-id pub-id-type="pmid">37496608</article-id><article-id pub-id-type="doi">10.1093/ofid/ofad339</article-id><article-id pub-id-type="publisher-id">ofad339</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Major Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>A Descriptive Cohort Study of Drug Utilization Patterns Among Patients Hospitalized With Coronavirus Disease 2019 in the United States, January 2021&#8211;February 2022</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Vititoe</surname><given-names initials="SE">Sarah E</given-names></name><aff>
<institution>Aetion, Inc</institution>, <addr-line>Scientific Research and Strategy, New York, New York</addr-line>, <country country="US">USA</country></aff><xref rid="ofad339-cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Govil</surname><given-names initials="P">Priya</given-names></name><aff>
<institution>Aetion, Inc</institution>, <addr-line>Scientific Research and Strategy, New York, New York</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baglivo</surname><given-names initials="A">Aidan</given-names></name><aff>
<institution>Aetion, Inc</institution>, <addr-line>Scientific Research and Strategy, New York, New York</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beebe</surname><given-names initials="E">Elisha</given-names></name><aff>
<institution>Aetion, Inc</institution>, <addr-line>Scientific Research and Strategy, New York, New York</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garry</surname><given-names initials="EM">Elizabeth M</given-names></name><aff>
<institution>Aetion, Inc</institution>, <addr-line>Scientific Research and Strategy, New York, New York</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gatto</surname><given-names initials="NM">Nicolle M</given-names></name><aff>
<institution>Aetion, Inc</institution>, <addr-line>Scientific Research and Strategy, New York, New York</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lasky</surname><given-names initials="T">Tamar</given-names></name><aff>
<institution>Office of the Commissioner, US Food and Drug Administration</institution>, <addr-line>Silver Spring, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chakravarty</surname><given-names initials="A">Aloka</given-names></name><aff>
<institution>Office of the Commissioner, US Food and Drug Administration</institution>, <addr-line>Silver Spring, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6266-4414</contrib-id><name name-style="western"><surname>Bradley</surname><given-names initials="MC">Marie C</given-names></name><aff>
<institution>Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration</institution>, <addr-line>Silver Spring, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perez-Vilar</surname><given-names initials="S">Silvia</given-names></name><aff>
<institution>Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration</institution>, <addr-line>Silver Spring, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rivera</surname><given-names initials="DR">Donna R</given-names></name><aff>
<institution>Oncology Center of Excellence, US Food and Drug Administration</institution>, <addr-line>Silver Spring, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2251-4160</contrib-id><name name-style="western"><surname>Quinto</surname><given-names initials="K">Kenneth</given-names></name><aff>
<institution>Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration</institution>, <addr-line>Silver Spring, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Clerman</surname><given-names initials="A">Andrew</given-names></name><aff>
<institution>Division of Pulmonology, Allergy, and Critical Care, Office of Immunology and Inflammation, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration</institution>, <addr-line>Silver Spring, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rajpal</surname><given-names initials="A">Anil</given-names></name><aff>
<institution>Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration</institution>, <addr-line>Silver Spring, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Frajzyngier</surname><given-names initials="V">Vera</given-names></name><aff>
<institution>Aetion, Inc</institution>, <addr-line>Scientific Research and Strategy, New York, New York</addr-line>, <country country="US">USA</country></aff><xref rid="ofad339-cor1" ref-type="corresp"/><xref rid="ofad339-FM1" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="ofad339-cor1">Correspondence: Vera Frajzyngier, PhD, Aetion, Inc, 5 Pennsylvania Plaza, New York, NY 10001 (<email>vera.Frajzyngier@aetion.com</email>); Sarah Vititoe, MPH, Aetion, Inc, 5 Pennsylvania Plaza, New York, NY 10001 (<email>aetion.studies@aetion.com</email>).</corresp><fn id="ofad339-FM1" fn-type="COI-statement"><p>
<italic toggle="yes">
<bold>Potential conflicts of interest</bold>
</italic>. S. E. V., P. G., A. B., E. B., E. M. G., N. M. G., and V. F. are employees of Aetion, Inc, with stock options. All other authors report no potential conflicts.</p></fn></author-notes><pub-date pub-type="collection"><month>7</month><year>2023</year></pub-date><pub-date pub-type="epub" iso-8601-date="2023-07-10"><day>10</day><month>7</month><year>2023</year></pub-date><volume>10</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">439658</issue-id><elocation-id>ofad339</elocation-id><history><date date-type="received"><day>17</day><month>1</month><year>2023</year></date><date date-type="editorial-decision"><day>27</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>06</day><month>7</month><year>2023</year></date><date date-type="corrected-typeset"><day>25</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>10</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-10 00:25:24.407"><day>10</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.</copyright-statement><copyright-year>2023</copyright-year><license><license-p>This work is written by (a) US Government employee(s) and is in the public domain in the US.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ofad339.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ofad339.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>There is a dearth of drug utilization studies for coronavirus disease 2019 (COVID-19) treatments in 2021 and beyond after the introduction of vaccines and updated guidelines; such studies are needed to contextualize ongoing COVID-19 treatment effectiveness studies during these time periods. This study describes utilization patterns for corticosteroids, interleukin-6 (IL-6) inhibitors, Janus kinase inhibitors, and remdesivir among hospitalized adults with COVID-19, over the entire hospitalization, and within hospitalization periods categorized by respiratory support requirements.</p></sec><sec id="s2"><title>Methods</title><p>This descriptive cohort study included United States adults hospitalized with COVID-19 admitted from 1 January 2021 through 1 February 2022; data included HealthVerity claims and hospital chargemaster. The number and distribution of patients were reported for the first 3 drug regimen lines initiated.</p></sec><sec id="s3"><title>Results</title><p>The cohort included 51 066 patients; the most common initial drug regimens were corticosteroids (23.4%), corticosteroids plus remdesivir (25.1%), and remdesivir (4.4%). IL-6 inhibitors and Janus kinase inhibitors were included in later drug regimens and were more commonly administered with both corticosteroids and remdesivir than with corticosteroids alone. IL-6 inhibitors were more commonly administered than Janus kinase inhibitors when patients received high-flow oxygen or ventilation.</p></sec><sec id="s4"><title>Conclusions</title><p>These findings provide important context for comparative studies of COVID-19 treatments with study periods extending into 2021 and later. While prescribing generally aligned with National Institutes of Health COVID-19 treatment guidelines during this period, these findings suggest that prescribing preference, potential confounding by indication, and confounding by prior/concomitant use of other therapeutics should be considered in the design and interpretation of comparative studies.</p></sec></abstract><abstract abstract-type="teaser"><p>This study provides an updated overview of inpatient COVID-19 drug utilization from January 2021 to February 2022, and suggests that prescribing preference and confounding by indication and prior treatments may influence the results of ongoing and future COVID-19 studies.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="anchor" id="ofad339-ofad339_ga1" orientation="portrait"><label>Graphical abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ofad339_ga1.jpg"/></fig>
</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>drug utilization</kwd><kwd>interleukin-6 inhibitors</kwd><kwd>Janus kinase inhibitors</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>US FDA</institution><institution-id institution-id-type="DOI">10.13039/100000038</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Broad Agency Announcement</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Aetion Evidence Platform</institution></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>